A Phase 1/2a Multicenter Open-Label First in Human Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of DB-1303 in Patients with Advanced/Metastatic Solid Tumors
Brief description of study
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303 in subjects with advanced solid tumors that express HER2.
Clinical Study Identifier: s22-00655
ClinicalTrials.gov Identifier: NCT05150691
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
